Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Weight Loss in Advanced Lung Disease
NCT05746039Phase 2Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of semaglutide in obesity, sponsored by University of Pennsylvania. Primary endpoint: Tolerability at 12 weeks. Started Jan 2024; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05746039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05746039.